• Media type: E-Article
  • Title: Combined Treatment with Interleukin-12 and Indomethacin Promotes Increased Resistance in BALB/c Mice with EstablishedLeishmania majorInfections
  • Contributor: Li, Jian; Padigel, Udaikumar M.; Scott, Phillip; Farrell, Jay P.
  • Published: American Society for Microbiology, 2002
  • Published in: Infection and Immunity, 70 (2002) 10, Seite 5715-5720
  • Language: English
  • DOI: 10.1128/iai.70.10.5715-5720.2002
  • ISSN: 1098-5522; 0019-9567
  • Keywords: Infectious Diseases ; Immunology ; Microbiology ; Parasitology
  • Origination:
  • Footnote:
  • Description: ABSTRACTFollowing infection of susceptible BALB/c mice withLeishmania major, early production of interleukin-4 (IL-4) is associated with the development of a nonprotective Th2 response and the development of progressive disease. Treatment of mice with IL-12 at the time of infection can promote the activation of a protective Th1 response; however, IL-12 treatment of mice with established infections has little effect on the progress of lesion development. This may be due to a down-regulation of the IL-12 receptor β2 chain (IL-12Rβ2) that accompanies the expansion of IL-4-producing Th2 cells. We have examined whether prostaglandins function to regulate in vivo responsiveness to IL-12. Mice treated with indomethacin are responsive to treatment with exogenous IL-12 through at least the first 2 weeks of infection and, unlike control mice treated with IL-12, develop an enhanced Th1-type response associated with increased enhanced resistance to infection. Cells from indomethacin-treated mice also exhibit enhanced production of gamma interferon (IFN-γ) following in vitro stimulation with IL-12. Although in vivo indomethacin treatment did not appear to influence IL-12 production in infected mice, cells from indomethacin-treated mice did express higher levels of IL-12Rβ2, suggesting that prostaglandins may play a role in the loss of IL-12 responsiveness observed during nonhealingL. majorinfections.
  • Access State: Open Access